Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zunsemetinib + Methotrexate in Moderate to Severe Rheumatoid Arthritis
NCT04247815Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Mar 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ATI-450 + MTX with Placebo + MTX (2 arms). Primary endpoint: Adverse Events at Day 114. Started Mar 2020; status: completed.
02
Drugs
zunsemetinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04247815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247815.